OTCMKTS:ARPOAerpio Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aerpio Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.53 +0.21 (+15.91 %) (As of 08/5/2020 03:30 PM ET) Add Compare Share Today's Range$1.43Now: $1.53▼$1.8350-Day Range$1.19MA: $1.30▼$1.5352-Week Range$0.42Now: $1.53▼$1.62Volume28.24 million shsAverage Volume1.22 million shsMarket Capitalization$62.10 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema. It also develops ARP-1536, a humanized monoclonal antibody that is in late stage preclinical development for the treatment of wet age-related macular degeneration; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a Phase 1a clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio.Read More Beat the Market (BTM) Rank™ 1.0 Analyst's Opinion Consensus RatingAerpio Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.50, Aerpio Pharmaceuticals has a potential downside of 2.0% from its current price of $1.53.Amount of Analyst CoverageAerpio Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesAerpio Pharmaceuticals has received 96 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAerpio Pharmaceuticals has received 101 “underperform” votes. (Add your “underperform” vote.)Community SentimentAerpio Pharmaceuticals has received 51.27% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Aerpio Pharmaceuticals and other stocks. Vote “Outperform” if you believe ARPO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ARPO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAerpio Pharmaceuticals does not currently pay a dividend.Dividend GrowthAerpio Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aerpio Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders38.60% of the stock of Aerpio Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.37% of the stock of Aerpio Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 1.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.88 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ARPO Previous Symbol CUSIPN/A CIKN/A Webwww.aerpio.com Phone513-985-1920Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares40,588,000Market Cap$62.10 million Next Earnings DateN/A OptionableNot Optionable $1.53 +0.21 (+15.91 %) (As of 08/5/2020 03:30 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ARPO News and Ratings via Email Sign-up to receive the latest news and ratings for ARPO and its competitors with MarketBeat's FREE daily newsletter. Aerpio Pharmaceuticals (OTCMKTS:ARPO) Frequently Asked Questions How has Aerpio Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Aerpio Pharmaceuticals' stock was trading at $0.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ARPO shares have increased by 183.3% and is now trading at $1.53. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Aerpio Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerpio Pharmaceuticals in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Aerpio Pharmaceuticals. How were Aerpio Pharmaceuticals' earnings last quarter? Aerpio Pharmaceuticals Inc (OTCMKTS:ARPO) issued its earnings results on Thursday, May, 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.01. View Aerpio Pharmaceuticals' earnings history. What price target have analysts set for ARPO? 1 equities research analysts have issued 12 month price objectives for Aerpio Pharmaceuticals' stock. Their forecasts range from $1.50 to $1.50. On average, they anticipate Aerpio Pharmaceuticals' share price to reach $1.50 in the next twelve months. This suggests that the stock has a possible downside of 2.0%. View analysts' price targets for Aerpio Pharmaceuticals. What are Wall Street analysts saying about Aerpio Pharmaceuticals stock? Here are some recent quotes from research analysts about Aerpio Pharmaceuticals stock: 1. According to Zacks Investment Research, "Aerpio Pharmaceuticals Inc. is a biopharmaceutical company. It focuses on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye. The Company' product candidates include AKB?9778, ARP1536 and AKB-4924 which are in clinical stage. Aerpio Pharmaceuticals Inc. is based in Cincinnati, United States. " (7/13/2020) 2. HC Wainwright analysts commented, "Our price target is derived from an estimated market value of the firm at $43M, which includes a discounted cash flow- based asset value for AKB-9778 in glaucoma and AKB-4924 (GB004) in inflammatory bowel disease (IBS), using a 15% discount rate and 2% terminal growth rate, and probabilities of success at 20% and 10%,." (8/9/2019) Has Aerpio Pharmaceuticals been receiving favorable news coverage? News stories about ARPO stock have trended somewhat negative recently, according to InfoTrie. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aerpio Pharmaceuticals earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the near future. View the latest news about Aerpio Pharmaceuticals. Who are some of Aerpio Pharmaceuticals' key competitors? Some companies that are related to Aerpio Pharmaceuticals include Abeona Therapeutics (ABEO), Verastem (VSTM), Fortress Biotech (FBIO), IDEAYA Biosciences (IDYA), Selecta Biosciences (SELB), Milestone Pharmaceuticals (MIST), Strongbridge Biopharma (SBBP), Agile Therapeutics (AGRX), OrganiGram (OGI), Hookipa Pharma (HOOK), IVERIC bio (ISEE), Five Prime Therapeutics (FPRX), Aldeyra Therapeutics (ALDX), Aduro BioTech (ADRO) and Marinus Pharmaceuticals (MRNS). View all competitors. What other stocks do shareholders of Aerpio Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aerpio Pharmaceuticals investors own include Bausch Health Companies (BHC), Corbus Pharmaceuticals (CRBP), MannKind (MNKD), BIOLINERX LTD/S (BLRX), Actinium Pharmaceuticals (ATNM), AVEO Pharmaceuticals (AVEO), Biocept (BIOC), Catalyst Pharmaceuticals (CPRX), General Motors (GM) and Ovid Therapeutics (OVID). Who are Aerpio Pharmaceuticals' key executives? Aerpio Pharmaceuticals' management team includes the following people: Dr. Joseph H. Gardner, Founder, Pres & Director (Age 62)Mr. Kevin G. Peters M.D., Ph.D., Chief Scientific Officer & Sr. VP (Age 61)Dr. Stephen Pakola M.D., Chief Medical Officer (Age 49)Dr. Stephen J. Hoffman, CEO & Director (Age 64)Mr. Michael W. Rogers, Chief Financial Officer (Age 58) What is Aerpio Pharmaceuticals' stock symbol? Aerpio Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ARPO." How do I buy shares of Aerpio Pharmaceuticals? Shares of ARPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Aerpio Pharmaceuticals' stock price today? One share of ARPO stock can currently be purchased for approximately $1.53. How big of a company is Aerpio Pharmaceuticals? Aerpio Pharmaceuticals has a market capitalization of $62.10 million. What is Aerpio Pharmaceuticals' official website? The official website for Aerpio Pharmaceuticals is www.aerpio.com. How can I contact Aerpio Pharmaceuticals? Aerpio Pharmaceuticals' mailing address is 9987 CARVER ROAD, CINCINNATI OH, 45242. The company can be reached via phone at 513-985-1920 or via email at [email protected] This page was last updated on 8/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
